Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing by Patil, Rohan et al.
Optimized Hydrophobic Interactions and Hydrogen
Bonding at the Target-Ligand Interface Leads the
Pathways of Drug-Designing
Rohan Patil
1.¤, Suranjana Das
1., Ashley Stanley
1, Lumbani Yadav
1, Akulapalli Sudhakar
2,3,4,
Ashok K. Varma
1*
1Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, Maharashtra, India, 2Cell Signaling and Tumor Angiogenesis Laboratory, Boys Town
National Research Hospital, Omaha, Nebraska, United States of America, 3Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska,
United States of America, 4Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, United States of America
Abstract
Background: Weak intermolecular interactions such as hydrogen bonding and hydrophobic interactions are key players in
stabilizing energetically-favored ligands, in an open conformational environment of protein structures. However, it is still
poorly understood how the binding parameters associated with these interactions facilitate a drug-lead to recognize a
specific target and improve drugs efficacy. To understand this, comprehensive analysis of hydrophobic interactions,
hydrogen bonding and binding affinity have been analyzed at the interface of c-Src and c-Abl kinases and 4-amino
substituted 1H-pyrazolo [3, 4-d] pyrimidine compounds.
Methodology: In-silico docking studies were performed, using Discovery Studio software modules LigandFit, CDOCKER and
ZDOCK, to investigate the role of ligand binding affinity at the hydrophobic pocket of c-Src and c-Abl kinase. Hydrophobic
and hydrogen bonding interactions of docked molecules were compared using LigPlot program. Furthermore, 3D-QSAR
and MFA calculations were scrutinized to quantify the role of weak interactions in binding affinity and drug efficacy.
Conclusions: The in-silico method has enabled us to reveal that a multi-targeted small molecule binds with low affinity to its
respective targets. But its binding affinity can be altered by integrating the conformationally favored functional groups at
the active site of the ligand-target interface. Docking studies of 4-amino-substituted molecules at the bioactive cascade of
the c-Src and c-Abl have concluded that 3D structural folding at the protein-ligand groove is also a hallmark for molecular
recognition of multi-targeted compounds and for predicting their biological activity. The results presented here
demonstrate that hydrogen bonding and optimized hydrophobic interactions both stabilize the ligands at the target site,
and help alter binding affinity and drug efficacy.
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Introduction
Advances in the field of structural biology have provided
tremendous opportunities for computational biologists to design
small-molecule drug leads with better biological activity and
minimal side effects for a disease-specific target. Modern
bioinformatics tools could reduce the time needed to prioritize
lead compounds. Scientists have been paying more attention to in-
silico approaches since the first peptide-based HIV protease
inhibitors were developed [1], followed by a target for antihyper-
tension [2], inhibitors of the influenza virus [3] and H5N1 avian
influenza [4–5], using a structure-based drug design [6–10]. Even
with such advances, designing a novel anti-cancer drug that works
effectively on a patient is still out of reach. Considering the role of
protein structures in predicting protein function, we assume that
the complexity of each disease can be unraveled if the structure of
disease-associated molecules can be accurately visualized in three
dimensions at the atomic level. The protein structure provides
information about the precise position of each atom and the
molecules present in crystallographic forms. This helps in
elaborating the location of an active site at the molecular surface
of the protein structure where active ligands can be placed.
Weak intermolecular interactions play an important role in
stabilizing a ligand energetically at the interface of a protein
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12029structure. In this study, we have explored the effect of weak
intermolecular interactions on the binding affinity between ligand-
protein complexes in order to improve drug efficacy [11–13].
Studies of strong covalent bonds, weak hydrophobic interactions
and hydrogen bonds raise more questions than have been
previously answered [14]. If energetically stabilized drug-like
compounds are trapped at the bioactive core of the target site,
holding all the biochemical and conformational features, then how
is the side effect manifested? How is the binding affinity between
drug-ligand complexes associated with drug efficacy? If a suitable
environment is provided, are hydrophobic interactions and
hydrogen bonds interchangeable? Furthermore, computational
biologists (in-silico) are challenged to find supporting factors that
bring long-range associated ligand-target complex molecules into
small regions where biological activity can be altered. To resolve
all these issues, a multi-model approach is needed that explores the
dynamic nature of weak intermolecular interactions at the target-
drug interface.
An increased number of protein structures in the Protein Data
Bank have also provided novel opportunities for scientists and
clinicians to visualize disease-associated molecules in three
dimensions. A drug lead can be designed at the active core of
the protein-ligand interface, where the binding affinity is
dominated by a small number of atoms [15–17]. The predicted
hierarchical pathways depicted in Fig. 1 show in-silico optimiza-
tion of the role of weak intermolecular interactions between the
ligand-target binding affinity and biological activity. This infor-
mation will encourage scientists to study the interrelationship
between hydrophobic interactions and hydrogen bonding when
developing new drugs. Most ligands exhibits low binding affinity
and thus, they can select the number of targets associated with
hydrogen bonds [18] (Fig. 1A), however, tight binding is observed
if hydrophobic interactions are optimized at the expense of
hydrogen bonds [19] (Fig. 1B) This schematic representation
reveals that low-affinity binders, such as 4-amino substituted
pyrimidine derivatives, can be selected and screened for biological
activity in a multi-targeted structural environment. Furthermore,
incorporation of functional group or metal atoms at the ligand site
or target site can increase specificity and binding affinity for one of
the target (Figs 1C i, ii, iii) even as, major unanswered questions
may still need re-evaluation. Does this modified target-drug
interface; (1) improve binding affinity, (2) help in finding a specific
target, and (3) improve drug efficacy for drug design? To find the
answers to these questions focused studies are required to evaluate
Figure 1. Conformational association of an energetically favored ligand and specific target. The ligand is associated to the specific target
with hydrogen bonds and hydrophobic interactions inferring the biological activity of compounds. (A) The hypothetical model where the ligand is
forming hydrogen bonds to target. (B) The ligand is associated with hydrophobic interactions. (Ci) target is modified. (Cii) ligand is modified. (Ciii)
ligand is allied with metal-associated hydrogen bonds for a specific target showing the interrelation between long-range hydrogen bonds and
hydrophobic interactions.
doi:10.1371/journal.pone.0012029.g001
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However, finding a suitable target for drug design and
development, using structure-based activity relationships, is not a
biased approach. Currently, computational biologists face the
challenges of designing small molecule inhibitors using experi-
mentally determined structures and improving the biological
activity of drug-leads.
To initiate a new approach for drug- design and development,
the atomically resolved structure at the ligand-protein interface
(i. e, a hot point) is needed [20], In this approach, the positions of a
few atoms are stabilized by the number of biophysical parameters
such as size, shape, molecular weight, hydrogen bonds, hydro-
phobic interactions, van der Waals forces and salt bridges [21–22].
Hence, any small molecule that binds to a target loses its internal
freedom, translational and rotational entropy [23]. After analyzing
the interactions that are important for stabilizing the protein-
ligand complexes, the focus shifts to the surrounding regions of the
hot spot (i.e., the hot regions). Here, the hydrophobic –pocket-
associated hot spot and hot regions between 4-amino substituted
small molecules and the c-Src [24] and c-Abl [25] protein kinase,
have been focused. It is well known that kinases are structurally
flexible, thus the dynamic nature of the weak intermolecular
interactions of 4-amino-substituted dock molecules at the target-
ligand interface can be elaborated.
Kinases are well known for their important role in signal
transduction pathways [26]. More than 90 known tyrosine kinases
are present in the human genome, Fifty-eight of these are receptor
tyrosine kinases and 32 are non-receptor tyrosine kinases. The
v-Src protein was the first recognized membrane-bound non-
receptor tyrosine kinase. A mutated v-Src protein shows the same
characteristics as cellular- Src (c-Src) kinase. Cellular-Src encodes
536 amino acids, whereas Abelson Leukemia viral oncogene
homolog 1 (Abl) encodes 1130 amino acids. However, both
proteins contain SH3, SH2, and nucleotide- binding functionally
important domains.
These bioactive core of c-Src and c-Abl have less sequence
similarity (,45%) and good three dimensional structural resem-
blance (,75%) whereas docked 4-amino-substituted compounds
have a majority of hydrophobic atoms. This conformationally
diversified interface between c-Src and c-Abl protein kinases and
4-amino-substituted dual inhibitors [27] stimulated interest in the
optimization of hydrophobic interactions and 3D structural
folding at the protein-ligand interface. The inhibitor binding
pocket of c-Src and c-Abl is primarily dominated by hydrophobic
interactions that play a major role in the binding affinity between
proteins and ligands. The comparative structure analysis of both
the protein c-Src (PDB ID: 2H8H) and c-Abl (PDB ID: 2FO0) has
shown conformational diversity with the rmsd of Ca (carbon-
alpha) .10 A ˚. Despite this change in the rmsd, the overall
structural folding at the active core is identical. Since the
functional site of the c-Src and c-Abl has a similar folding, it
helps the 4-amino substituted inhibitors recognize the binding sites
of both the targets. Therefore, it can also be concluded that in
addition to low-affinity binding, the protein folding at the
biologically active sites should be identical (Fig. 2A and
Fig. 2B) if an inhibitor is going to be able to recognize multi-
targets. Dual inhibitors or multi-targeted drug leads for a given
protein structure can be designed based on: (1) sequence similarity,
(2) structural similarity at the active site, (3) binding affinity, and (4)
the source of drug lead. Taking all these elements under
consideration, efforts were made to understand the drug efficacy
by incorporating the hydrophobic interactions at the expense of
hydrogen bonding at the target-ligand interface.
Results and Discussion
Novel classes of disease- modifying drugs, and their associated
targets, are very important for studying the structure activity
relationship. The presence of a drug lead in proximity to an active
pocket of a target site will show a better biological efficacy when
compared to a drug lead that is not in close proximity. However,
binding affinity of long-range associated target and ligand
molecules can be tailored several ways: (1) by optimizing the
weak intermolecular interactions, (2) by engineering the active
pocket in which the ligand binds, (3) by engineering the
Figure 2. Sequence and structural alignment of c-Src and c-Abl kinase. (A) The sequence and secondary structure alignment of c-Src and c-
Abl; sequence alignment of c-Src and c-Abl has been carried out using ClustalW. The secondary structure assigned with the SSEA server is depicted as
orange cylindrical (alpha helices) and light-blue arrows (beta-strand). (B) Three-dimensional structural alignments of c-Src and c-Abl kinases;
superimposed structure of c-Src (PDB ID 2H8H) and c-Abl (PDB ID 2FO0); color coding for the ribbon diagram of c-Src is sand yellow and for c-Abl is
split-pea-green color. This figure was made using PyMOL program (www.pymol.org).
doi:10.1371/journal.pone.0012029.g002
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of ions or heavy atoms at the ligand-target interface. Should any of
these instances occur, the efficacy of the ligand (a drug-like
compound) would be expected to change (Fig. 1)? Multi-targeted
compounds are low-affinity binders and could become more
prominent for a specific target, provided they are exposed to an
external conformationally- favored functional group [28]. It has
also been reported that binding affinity is a function of the stability
of the ligand-target complex formation and further optimize the
new bonds that affect the biological activity of a complex molecule.
This has been observed recently on dihydropyrancarboxyamides -
related zanamivir [29]. Considering these findings, docking studies
of 4-amino substituted 1H-pyrazolo [3, 4-d] pyrimidine com-
pounds on c-Src and c-Abl kinases associated with weak
hydrophobic interactions, were analyzed. The results presented
in this paper provide a novel in-silico based approach to design
drug-lead at the hydrophobic core of the protein–ligand interface.
The experimentally determined biological activities of inhibitor
molecules are align with what has been calculated in-silico.
Molecular Field Analysis (MFA)
Since 1991, the field of drug discovery has used the Quantitative
Structure-Activity-Relationship (QSAR) approach in to optimize
the drug leads [30]. This method has been successfully used in
studies focusing on material molecules, biopolymers, and antigen-
antibody interactions [30–32]. The QSAR equation was gener-
ated using a field value of 700 grid points, with grid dimensions x
(210.883, 7.117), y (26.401, 11.599), z (26.520, 5.480), for
Molecular Field Analysis (MFA). Thirty-nine compounds of 4-
amino-substituted active derivatives were taken as training set and
a QSAR equation were generated for c-Src and c-Abl kinase. This
QSAR equation was further randomized and cross-validated using
the residual data acquired from all the models. We observed a very
good agreement between the actual and predicted activity in the
unit of Ki and good alignment of all the thirty-nine training set
molecules (Table S1). In the training set, it is seen that increasing
the size of the R chain decreases the activity as seen in 2 and 39,
which are less biologically active than compound 28. The presence
of electronegative elements in compounds 19 and 20 shows better
activity than in compounds 11 and 13. In c- Src the bulkier group
at the R2 position seems to decrease in activity. The increase in
the size of R1 shows an increase in activity of c-Src. However, the
results are reverse in the case of c-Abl as seen in compound 12.
The quantitative observation of MFA and structural analysis
showed that Leu 273, Thr 338 and Leu 393 are amino acids that
are conserved in the hydrophobic binding pocket of c-Src, whereas
Leu 248, Tyr 253, Ala 269, Gly 321, Leu 370 and Phe 382 are
conserved in c-Abl (Fig. 3A and Fig. 3B).
Based on the QSAR equation, the biological activities of the test
set were calculated for 103 compounds. The top 20 best scoring
molecules were selected from the top-ranked hit conformations,
with a correlation coefficient (r
2) value 0.936 for c-Src and 0.975
for the c-Abl model. The scoring function of the top 20 test-set
molecules is listed in Table S2. However in order to compare the
conformational changes with the biological activity, this study only
analyzed the compounds having high and low scoring values for c-
Src and c-Abl. The key amino acids responsible for interactions
are mentioned in Fig. 3C. A summary of the MFA results is listed
in Table 1. It was observed from the test set that molecule 4 can
be a dual inhibitor, as it showed better biological activity for both
c-Src and c-Abl. These results could be due to the presence of
para-fluorine at the R2 position. In c-Src molecule 1, which has a
chlorine phenyl substitution in the R2 side chain shows optimum
biological activity, where as molecule 13 is seen to be the least
active compound having the bulky group at R1 side chain. But in
the c-Abl ligand, the occurrence of bromine and fluorine at the R2
position is the most active. It has been reported that the binding
affinity associated with fluorine is remarkably different than the
binding affinity associated with other halogens such as Cl, Br, I
[11]. Thus, it can be inferred that the halogen substitution at the
R2 position has a profound effect on the Ki values. This in-silico
prediction for having heavy atom at the ligand–target interface
that optimizes hydrophobic interactions and changes the func-
tional activity for a specific target is evidenced by the experimental
results. In Fig. 4A shows the presence of a docked metal atom,
while Fig. 4B shows the presence of a crystallographically
determined sulfate atom. After superimposing a docked model
upon the crystal structure, it has been observed in Fig. 4C that the
docked atom is located in same part of the crystal structure where
the sulfate is positioned. This sulfate is stabilizing the hydrophobic
core of the c-Src–ligand complex.
Functional Sites Analysis
The overall rmsd of Ca of the superimposed c-Src (PDB ID
2H8H) and c-Abl (PDB ID 2FO0) structures using the CCP4i
program is .10 A ˚, this indicate that there is no hope of
considering one class of chemical groups or drug-like compounds
as dual inhibitors. Despite this great change in the rmsd, the
protein folding at the functional site of the c-Src and c-Abl has a
very good structural similarity, which helps the 4-amino
substituted inhibitors recognize the binding sites of both the
genes. This functionally important target-ligand orientation has
been confirmed by two approaches. In the first approach, the X-
ray crystal structure of c-Src (PDB ID 2H8H) and c-Abl (PDB ID:
2FO0) where the ligand for c-Src, quinazoline and c-Abl, 6-(2,6-
Dichlorophenyl)-2-{[3-(Hydroxymethyl) Phenyl]amino}- 8-
Methylpyrido [2,3-D] Pyrimidin-7 (8H)-One) were binding at
the surface groove of proteins was used. The docking of 4-amino
substituted compounds was performed onto the ligand removed
protein structure. It has been predicted that all the docked ligands
are finding the same position where the structurally predetermined
molecules are in place. Using this approach, we found that only a
predetermined position was sufficient for analyzing the different
parameters of enthalpy or entropy of ligands. The second
approach involved random docking of the 4-amino -substituted
compounds onto the ligand -removed protein structure of c-Src
(PDB ID 2H8H) and c-Abl (PDB ID 2FO0). In this approach, we
did the docking of the 4-amino substituted compounds in several
ways, such as fixing the c-Src and c-Abl protein structure and
docking the flexible ligands, or vice-versa. In this method, the
Binding Site Protocol generated a number of expected binding
sites. We selected the site having the maximum volume and
compared it with the ligand-bound crystal structure. In conclusion,
the position of the docked inhibitors at c-Src (PDB ID 2H8H) and
c-Abl (PDB ID 2FO0) looked identical in both approaches. The
biological activity, in the form of binding affinity, was also
identical. These results are listed in Table S2. Analyzing the
atomic orientations of the 4-amino- substituted inhibitors, we
observed that docking on structurally- known ligand-bound
bioactive sites is more defined than evaluating random docking.
Generally, docking transpires on the basis of shape and the
complementarity of the ligand and the protein structure. Ligand is
free to rotate and translate all over the target sites with fixed
discrete parameters such as contact area and active site volume.
However, the possibility of getting better conformation and atomic
specificity is more precise in first approach than in the second
approach, where both the ligands and the targets are dynamic.
Weak Interactions & Drug Design
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recognize multi-targets, the structural similarity at the active core
of the target sites also plays a crucial role. The superimposed
structure of c-Src and c-Abl predicts the difference in overall
conformation of a protein structure, but the ligands binding sites
for the 4-amino -substituted dual inhibitor look structurally
identical (Fig. 2B). The structure of the ligand-bound protein at
the binding site of the modeled structure, and the crystallograph-
ically determined X-ray structure has been compared. An identical
structural homology at the binding interface was predicted
(Fig. 4A and Fig.4B). The superimposed model and X-ray
structure predicted the identical position of the docked molecule at
the active site. This was observed from the position of the
crystallographically determined sulfate group and the computa-
tionally -docked metal ions (Fig. 4C). This docked metal ion
optimizes hydrophobic interactions at the outlay of hydrogen
bonding. These modified hydrophobic interactions enhance the
binding affinity and biological activity of complex molecules and
help in stabilizing the biochemical environments of target-drug
complexes.
Analysis of Hydrogen Bonds
The importance of hydrogen bonds in the binding affinity of a
target-drug has been described extensively [33]. Where as, how
hydrogen bonds optimize the hydrophobic interactions, at the
protein-ligand interface that increases the binding affinity of
complex molecules, has not been properly analyzed. In this paper,
we have studied the relative contribution of hydrogen bonds and
Figure 3. Ligand-associated amino acids of c-Src and c-Abl Kinase. (A) A stick model of active inhibitors 1, 12, 19 and 28 docked in c-Src with
conserved hydrophobic amino acids is shown. (B) Stick model of active inhibitors 1, 12, 19 and 28 docked in c-Abl with conserved hydrophobic amino
acids is shown. (C) Alignment of hydrophobic amino acids observed at the interface of c-Src (PDB ID 1Y57), c-Abl (PDB ID 1M52) and functionally
important inhibitors as listed in Table S1: (1, 12, 19 and 28). In figure (B) and (C), structure was aligned using COOT [43] and figure was made by
PyMOL program.
doi:10.1371/journal.pone.0012029.g003
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substituted compounds at the binding sites of c-Src and c-Abl.
Using LigandFit software, all 39 docked 4-amino-substituted
compounds as reported [27] were analyzed for hydrogen bonding
at the binding interface of c-Src and c-Abl. The default parameter
for the distance between the hydrogen bond donor and the
acceptor was 3.2 A ˚ and the donor proton-acceptor angles between
120–180u, were selected, but no hydrogen bonding, such as C-
H…O and O-H…O between the docked molecules and the
hydrophobic pocket of the c-Src and c-Abl proteins, was observed
(Fig. 5A and Fig. 5B). All the hydrogen bonds [33–35] and
hydrophobic interactions were analyzed using the LigPlot [36].
The same results were also observed in most of the docking
software including ZDOCK and CDOCKER. A change in
intermolecular interactions was observed using CDOCKER.
Minor changes in the conformation and position of ligands at
the active site of c-Src and c-Abl were also observed on docked
compounds (1, 12, 19 and 28) using different software like
LigandFit, CDOCKER and ZDOCK (data not shown). After
we found fewer changes in conformation of ligands at the docking
sites, we began manually analyzing the hydrogen bonds and
observed weak C-H…O interaction with an H…O distance of
.1.85 A ˚. This kind of weak hydrogen bond can be broken and
exchanged for another kind of bond, depending upon the chemical
environment at the target, ligand and target-ligand interface.
Hydrophobic Interactions and Functional Activity
The average number of hydrophobic atoms in marketed drugs
is 16, with one to two donors and three to four acceptors [37]. This
defines the importance of hydrophobic interactions in drug
designing. They can increase the binding affinity between target-
drug interfaces. It has been already reported that the binding
affinity and drug efficacy associated with hydrophobic interactions
can be optimized by incorporating them at the site of the hydrogen
bonding [38]. However, this approach is not the only leading
method for drug designing. Additionally, the presence of water
molecules in hydrophobic regions makes this region quite flexible.
There is also the probability of engineering either the drug or the
target, or the interface between the drug and the target, to increase
the binding affinity.
An increase in the number of hydrophobic atoms in the active
core of drug -target interface further increases the biological
activity of the drug lead. These loosely bound 4-amino
Table 1. Summary of MFA results.
MFA results c-Src c-Abl
r
2 0.936 0.975
Nobs 37.000 36.000
Nvars 15.000 15.000
LSE(Least square error of fit) 0.283 0.46
R(correlation coefficient) 0.968 0.987
BS r
2 0.917 0.767
PRESS 47.939 68.594
Dep SD 163.938 66.037
Dep Mean 2.695 0.789
Where r
2= Square of correlation coefficient,
Nobs= Number of observation,
Nvars =Number of terms in the equation,
BS r
2 (Bootstrap r
2) = Average squared correlation coefficient which is
calculated during the validation procedure,
PRESS = Predicted sum of square,
Dep SD = Sum of square deviations of the dependent variable values from
their mean.
Dep Mean = Mean of the dependent variable values.
doi:10.1371/journal.pone.0012029.t001
Figure 4. Correlation between crystallographically determined and computationally- generated modeled structure. (A) Heavy atom
was docked between the ligand and hydrophobic amino acid in c-Src. (B) The sulfate group was at the interface of the ligand and hydrophobic amino
acid. (C) Superimposed of (A) and (B) structure. All three figures were made by PyMOL program.
doi:10.1371/journal.pone.0012029.g004
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inhibitors of c-Src and c-Abl. The functional groups of 4-amino
substituent’s were modified in order to optimize the hydrophobic
interactions at the target-drug interface [30]. These optimized
hydrophobic interactions also influence the side effects and
toxicity, but to what extent? It has been reported that there are
certain pathological conditions in which a low-affinity binding
drug works efficiently with minimum side effects [39]. The
question arises: How is it possible to improve drug efficacy for
these low affinity binding ligands using an in-silico approach? Do
conformationally- favored heavy atoms play any role in
mediating the binding affinity? To test this assumption, we
performed Zn, Cd, Fe and Mn metal atom docking on the
inhibitor-docked structure of c-Src and c-Abl. We observed that
these atoms were sitting in the same part in the crystal structure
of c-Src where the crystallographically- determined atom was
located (Fig. 4A). This atom-docked model shows an increase in
both the binding affinity and in the hydrophobic interactions.
The sulfate helps in the crystallization of the c-Src protein. It
stabilizes the protein complex by mediating the interactions
between c-Src and the ligand (Fig. 4B). The superimposed
structure predicts the reliability of the docked results and the
accuracy of the prediction (Fig. 4C). In conclusion, these docked
atoms help increase the binding affinity of the target-receptor
molecules and optimize the hydrophobic interactions by capti-
vating the hydrogen bonding at the hydrophobic core of the
complex.
The ClustalW [40] sequence alignment score for c-Src (PDB ID
2H8H) and c-Abl (PDB ID 2FO0) is 38. The SuperPose [41]
alignment gives a 42% sequence identity and a 61% sequence
similarity, with a gap in sequence of 8.2% similarly. Observing less
sequence similarity of the conserved hydrophobic amino acids and
the good structural resemblance at the active core of c-Src and c-
Abl kinases became focused to understand the role of hydrophobic
interactions, binding affinity and the functional efficacy of ligands.
We turned T (Turn) to C (coil), G (310 helix) to H (Helix) and
removed the B (bridge) to compensate for the secondary structure.
SSEA [42] (Secondary Structure Element Alignment, a web-based
server) which resulted in a local secondary structure alignment
score of 75.62 and a global alignment of 84.058. Furthermore, we
observed secondary structure similarities even at the level of 310
helix besides high rmsd and low sequence similarity (Fig. 2A and
Fig. 2B). The average rmsd between c-Src (PDB ID: 2H8H) and
c-Abl (PDB ID: 2FO0) for Ca using CCP4i [43] is ,10 A ˚, and for
a side chain is ,12 A ˚. The superimposed structure of PDB ID
2H8H (c-Src) and PDB ID 2FO0(c-Abl) showed a conformational
divergence at the binding site, with an overall rmsd of Ca 9.65 A ˚
and for a side chain of 9.66 A ˚. Overall the structural fold at the
ligand binding site displayed a similar structural folding (Fig. 2B).
In this study, efforts have been made to reveal how few organic
residues can work as a dual inhibitor in such diversified targets. It
is very clear that hydrophobic interactions play a major role in
stabilizing the ligands at the binding interface (Fig. 5A and
Fig. 5B). A large number of hydrophobic atoms are present in
Figure 5. Hydrophobic interactions and hydrogen bonding between ligands and target. (A) Two-dimensional representations of
interactions observed between c-Src and ligands listed in Table S1: (1, 12, 19 and 28). (B) Two-dimensional representations of interactions observed
between c-Abl and ligands listed in Table S1: (1, 12, 19 and 28). Hydrogen bonds are depicted with dashed line and hydrophobic interactions are
shown as arcs. Both the figures were made using LIGPLOT program.
doi:10.1371/journal.pone.0012029.g005
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target binding. This structural environment, in which hydrophobic
interactions are optimized at the outlay of hydrogen bonds, can
induce a significant change in the biological activity of drug leads.
The discovery of influenza neuraminidase inhibitors provided an
example where hydrophobic interactions were optimized at the
expense of hydrogen bonding [44]. However a further question
arises: What could be the source of a heavy atom that can alter the
hydrogen bonding into hydrophobic interactions in-vivo? To
answer this question, an integrated in-silico, in-vitro, in-vivo effort
to study the comparative breakdown of structure at the molecular
level is needed.
Prospects
With fatal diseases, such as cancer, scientists and clinicians are
working to discover small molecule anti-cancer compounds.
However, the existing approach they are following has not been
very successful. Several researchers are screening drug-like
compounds using in-silico, in-vitro and in-vivo approaches, but
success is still far away. A comparative analysis of binding affinity
at the interface of 4-amino substituted compounds and c-Src and
c-Abl kinases has revealed that multi-targeted compounds can be
better single targeted, if optimized hydrophobic interactions and
hydrogen bonding increases its binding affinity. The increase in
binding affinity of complex molecules due to optimization of
hydrophobic interactions at the target-drug interface, compara-
tively demonstrate better efficacy of drug leads. This approach
would definitely encourage scientists to focus on weak intermo-
lecular interactions, such as hydrophobic interactions, hydrogen
bonding and metal-associated interactions for drug design, which
have not yet been comprehensively analyzed. The results reported
in this paper may help in designing new molecules with potent
biological activity and fewer side effects. However, all these
predictions are based on the in-silico approach that is not without
its drawbacks, deficiencies and limitations of predictive tools which
are also always present. Thus the predictions reported in this paper
cannot be considered as assets for medicinal counseling until they
are further optimized using in-vitro, in-vivo and clinic-based phase
trials. Nevertheless, this integrated approach may result in the
rational design of potential drugs to fight cancer.
Materials and Methods
Selection of Biological Data and Structures
Set of 39 molecules of 4-amino -substituted 1H-pyrazolo [3, 4-d]
pyrimidine compounds, along with their biological activity were
taken from Schenone et al [27] for training set are listed in Table
S1. The compounds under study belonged to the following
structurally diverse categories; Category A: Linear alkyl amino
substituted; Category B: Cyclic amino substituted and Category C:
Benzyl amino substituted compounds with fluorine (halogen) at the
meta -position.
The biological activity of each compound was compared with
Ki, i.e., the inhibitory activity of compounds. Ki value was used to
perform the calculations using Accelrys Cerius2 and Discovery
Studio software (DS).
Binding Sites and Binding Affinity Analysis
The binding sites in c-Src and c-Abl protein structures were
predicted by using the Binding Site module available in DS. The
default parameters in the software for grid size (grid resolution is
0.50 A ˚, which is the spaces between the grid, 100 points as the
minimum binding site, i.e. the minimum number of grid points for
the site) were used to predict the binding sites.
The Discovery Studio software module, LigandFit [45] was
used to compute the LigScore1 function in order to estimate the
binding affinity of the 39 molecules in the training set reported in
the units of pKi (-log Ki). To calculate binding affinity of a test set
in pKi, following equation was used in DS: pKi=A+(B vdW) +
(C c+pol)2(D BuryPol
2). LigScore1 is one of the scoring functions
of LigandFit. In this equation, there are three descriptors: (1)
vDW, Lennard-Jones 6–9 potential (kcal/mol); (2) c+pol, a count
of the burried polar surface area between c-Src, c-Abl and small
molecule 4-amino substituted inhibitor (A ˚ 2); and (3) BuryPol
2, the
squared sum of the burried polar surface area of the c-Src, c-Abl
and small molecule 4-amino substituted inhibitor molecule (A ˚ 2). A,
B, C and D are constant parameters that obtained through
regression analysis.
Calculation of rmsd and Cavity Volume of Proteins
The CCP4i [46] program was used to calculate the overall rmsd
of Ca (carbon-alpha) of the superimposed structure of c-Src (PDB
ID 2H8H) and c-Abl (PDB ID 2FO0). The cavity volume at the
binding sites was calculated, using DS (Binding Site module) for
the coordinates obtained from protein data bank (c-Src, PDB ID:
1YOL, 1Y57, 1FMK, 2H8H and for c-Abl, PDB ID: 1M52 and
2FO0). A binding site having maximum volume was selected
manually, as it should have the appropriate volume for a drug to
adopt minimal energy. The cavity volume of different proteins is
listed in the Table S3.
Molecular Modeling and Docking
All the molecular models were built using Accelrys DS. A
CHARMM force field [47] was applied to each model to stabilize
the coordinate from thermodynamic environments and to remove
some steric clashes and bad contacts between the ligand and
target. PDB ID: 1Y57 (the X-ray crystal structure of a human
tyrosine-protein kinase c-Src) and 1M52 (the crystal structure of a
c-Abl kinase domain) coordinates were used to dock the 39 dual
inhibitors [27]. The LigandFit module [45] from Discovery Studio
was used to perform the docking, based on shape-based searching
and Monte Carlo methods. While docking, the variable trials
Monte Carlo conformation was applied where the number of steps
depends on the number of rotatable bonds in the ligand. By
default, the torsions number is 2, the number of trials is 500 and
the maximum successive failure is 120. Furthermore, protein-
ligand interactions were evaluated with Ligscore1, hydrogen
bonding and vDW functions. The position of docked molecules
was also re-evaluated, using ZDOCK and CDOCKER docking
software. Different coordinate files (PDB) were selected to confirm
the position of dock molecules independently. The rmsd of
different docked ligand at the ligand binding modes is given in
Table S4.
Molecular Field Analysis (MFA)
Using Cerius2 (Accelrys software Inc) QSAR module, MFA was
performed for all the training set as well as the test set molecules, to
quantify the interaction energy for a set of 3D structures between
the target and the ligand molecules. The field was generated at
each grid point (700 points) of the rectangular grid, which is
regularly spaced at 2.0 A ˚ with grid dimensions x (210.883, 7.117),
y( 26.401, 11.599), z (26.520, 5.480). In addition, a number of
spatial and structural descriptors such as polarizability, dipole
moment, radius of gyration, molecular area, molecular dimension,
density, principal moment of inertia, molecular volume, molecular
weight, number of rotatable bonds, hydrogen bond donors and
acceptors, AlogP, and molar refractivity were also calculated along
with the molecular field. Regression analysis was carried out using
Weak Interactions & Drug Design
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5000 generations with a population size of 100. The truncate
energy cut off for both steric and electrostatic grid was between
230 to +30 Kcal. Cross-validation was performed with the leave-
one–out principle to provide an almost unbiased estimate of the
model. The QSAR equation generated by MFA for the 39
molecules of the training set and Scatter-plot of actual versus
predicted activity for c-Src and c-Abl are shown in File S1. Using
this QSAR equation, a test set was generated and the best 20 were
selected on the basis of predicted biological activity against c-Src
and c-Abl.
Supporting Information
File S1 The QSAR equation and Scatter-plot of actual versus
predicted activity for c-Src and c-Abl.
Found at: doi:10.1371/journal.pone.0012029.s001 (0.09 MB
DOC)
Table S1 The training set of 39 molecules of 4-amino
substituted, with their biological activity and structural alignment.
Found at: doi:10.1371/journal.pone.0012029.s002 (0.48 MB
DOC)
Table S2 The test set of 20 molecules of 4-amino substituted,
with their biological activity.
Found at: doi:10.1371/journal.pone.0012029.s003 (0.06 MB
DOC)
Table S3 Cavity volume in the protein structures of c-Src and
c-Abl selected for docking.
Found at: doi:10.1371/journal.pone.0012029.s004 (0.03 MB
DOC)
Table S4 RMSD values of ligands (only for the molecules 1, 12,
19 and 28) at binding site of c-Src and c-Abl measured using
different algorithms.
Found at: doi:10.1371/journal.pone.0012029.s005 (0.04 MB
DOC)
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